RBC Capital lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares following a transfer of coverage. The stock price reflects an overly pessimistic view of MannKind’s commercial products, especially the Tyvaso DPI royalties, and assigns no value to the pipeline, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind assumed with a Buy at H.C. Wainwright
- MannKind’s Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment
- MannKind’s Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid
- MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data
- MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation